



Astec LifeSciences Ltd.

Date: 27th April, 2026

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai - 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai - 400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited ("the Company"), at its Meeting held on **Monday, 27th April, 2026**, has approved the Audited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31st March, 2026.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236



ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

CONSOLIDATED FINANCIALS FOR Q4 FY26 RESULTS

Mumbai, 27th April 2026: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the fourth quarter & Year ended March 31, 2026.

FINANCIAL OVERVIEW

Q4 FY26 Financial Summary

- *The Company reported consolidated total income of ₹161.3 crore in Q4FY26 as compared to ₹120.3 crore in Q4FY25.*
- *The Company reported consolidated EBITDA of ₹11.8 crore in Q4FY26 as compared to EBITDA of ₹6.3 crore in Q4FY25.*
- *The Company reported a Loss after tax of ₹7.7 crore in Q4FY26 as compared to a loss of ₹16.1 crore in Q4FY25.*

FY26 Financial Summary

- *The Company reported consolidated total income of ₹453.2 crore in FY26 as compared to ₹386.9 crore in FY25.*
- *The Company reported consolidated EBITDA Breakeven of ₹0.5 crore in FY26 as compared to EBITDA loss of ₹60.6 crore in FY25.*
- *The Company reported a Loss (after exceptional items* and tax) of ₹80.9 crore in FY26 as compared to a loss of ₹134.7 crore in FY25.*

Pursuant to the notification of four Labour Codes by the Government of India, the Group has assessed the incremental financial impact based on draft rules and ICAI guidance. The impact arising primarily from the revised wage definition—gratuity ₹1.7 crore and long-term compensated absences of ₹0.4 crore —has been classified as **Exceptional Items due to its regulatory-driven and non-recurring nature, with ongoing monitoring of final rules.*

HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE

(in ₹ crore)

Particulars (₹ crore)	Q4FY26	Q4FY25	% Change	FY25-26	FY24-25	% Change
Total Income	161.3	120.3	34.0%	453.2	386.9	17.1%
Earnings before depreciation, interest and taxes (EBITDA) (before Exceptional Items)	11.8	6.3	86.9%	0.5	(60.6)	NM
Profit/(Loss) (before Exceptional Items and Tax)	(7.9)	(15.7)	NM	(78.9)	(141.0)	NM
Profit/(Loss) after Exceptional items and Tax	(7.7)	(16.1)	NM	(80.9)	(134.7)	NM

NM: Not Measurable

CHAIRPERSON'S COMMENTS

Commenting on the performance, Mr. Vishal Sharma, Chairperson, Astec LifeSciences Limited, said:

In Q4FY26, Astec delivered strong revenue growth of 34% y-o-y primarily on the back of improved volumes in both the categories, i.e. Enterprise and Contract Manufacturing segment. Revenue increased sequentially as well by 29% over Q3FY26, primarily driven by Enterprise Volumes.

Improved volumes in the Enterprise and CDMO segments drove a significant margin expansion, leading to an increase in EBITDA to ₹11.8 crore in Q4FY26 from ₹6.3 crore in Q4FY25, an 87% y-o-y growth.

(in ₹ crore)

Revenue from Operations (₹ crore)	Q4FY26	Q4FY25	% Change	FY25-26	FY24-25	% Change
Category Breakdown						
Enterprise	69.2	50.5	37.1%	213.4	177.0	20.6%
Contract Manufacturing & New Products	89.4	69.0	29.5%	234.7	204.3	14.9%
Geography Breakdown						
Exports	103.7	96.0	8.0%	277.4	259.9	6.7%
Domestic	54.9	23.5	133.8%	170.7	121.4	40.6%

- ENDS -

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 18 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovet.com
Tel No.: +91 22 2519 4864

Deepak Ochani
Astec LifeSciences Limited
Email: deepak.ochani@godrejastec.com
Tel No.: +91 22 2519 5777

Amit Pendse
Godrej Agrovet Limited
Email: amit.pendse@godrejagrovet.com
Tel No.: +91 22 2519 4488

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."